Analyst outperform ratings on Crispr stocks.

in crispr •  7 years ago 

Cowen, Barclays and ROTH all host healthcare conferences next week;

• Intellia Therapeutics (NASDAQ:NTLA) initiated with Outperform rating and $76 (158% upside) price target at JMP Securities.

• CRISPR Therapeutics (NASDAQ:CRSP) initiated with Outperform rating and $69 (34% upside) price target at JMP.


With this, I’ll likely hold my Crispr theme options (EDIT and NTLA) for a medium/long term instead. 

crispr stock trading ntla
7 years ago by

Downvoting a post can decrease pending rewards and make it less visible. Common reasons:

  • Disagreement on rewards
  • Fraud or plagiarism
  • Hate speech or trolling
  • Miscategorized content or spam

Submit
$0.00
    0
    Authors get paid when people like you upvote their post.
    If you enjoyed what you read here, create your account today and start earning FREE STEEM!